New Delhi: The pace of vaccination in the country has also picked up pace to tackle the corona crisis. The company itself has reported this. Kapani said that another new breakthrough was achieved. This week we have started making the first consignment of the Covovax Covid vaccine. The vaccine has been made by US biotechnology firm Novavax, which has been named Covovax in India.

Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! pic.twitter.com/K4YzY6o73A

? Adar Poonawalla (@adarpoonawalla) June 25, 2021

Adar Poonawala, CEO of the same Serum Institute, also tweeted about the same. He said "I am excited to see the first batch of Covovax. The first batch is being prepared in Pune from this week. This vaccine has a great potential to protect our future generations under the age of 18. Trials are going on.?

Also, the late stage trial of Novavax vaccine has observed that the vaccine is 90 against medium and serious disease caused by SARS-Cov-2. 4 per cent is effective. In August 2020, under the agreement, Novavax had licensed SII to manufacture and supply vaccine in low and middle income countries as well as in India. Serum has tied up with Novavax Company to prepare 200 million doses. Earlier, NITI Aayog member (Health) V K Paul had said that publicly available data indicates that Novavax vaccine is safe and very effective.

Also Read

Supreme Court panel: Delhi govt exaggerated oxygen need by four times

In Kupwara LoC infiltration bid fails, heroin worth crores seized

U.P. Bank guard opens fire at a customer trying to enter without mask